Shots:
- The P-III (ADorable‑1) study data assessed Ebglyss vs PBO in 363 pediatric pts (≥6mos.) with mod. to sev. AD; Topical corticosteroids were required for 2 wks. pre-randomization through Wk. 16, with tapering or discontinuation allowed once pts achieved IGA ≤2
- At Wk. 16, the trial met it 1EP & key 2EPs, with 63% vs 22% achieving EASI-75, 44% vs 15% achieving IGA 0/1 with ≥2-point improvement, & 39% vs 11% achieving EASI-90; also, 35% vs 6% of pts (≥6yrs) achieved a ≥4-point improvement in pruritus NRS
- The ADorable program is ongoing, with additional data from ADorable-1 & ADorable-2, a 52wk. extension of ADorable-1, expected later this year, with results planned for submission to US & global regulators for a potential label update
Ref: Eli Lilly | Image: Eli Lilly | Press Release
Related News: Eli Lilly Reports the P-IIIb (TOGETHER-PsO) Trial Data on Taltz + Zepbound for Adults with Psoriasis and Obesity or Overweight
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
S
